Answers are grounded in this paper and cite their sources.
Analysis reveals novel fold of selenoprotein SEP15 in endoplasmic reticulum, highlighting its role with UGGT.
Proteins targeted to the secretory pathway are involved in a myriad of biological processes but can only do so when properly folded. Within the endoplasmic reticulum, glycoprotein folding is regulated by the enzyme UDP-glucose:glycoprotein glucosyltransferase (UGGT) and its oxidoreductase partner, the 15-kDa selenoprotein (SEP15 aka SELENOF). The interaction between these two chaperones is poorly understood, limiting understanding of their function. SEP15 is comprised of two domains, a C-terminal thioredoxin-like domain, the structure of which has been reported (PDB 2A4H), and an approximately 50-residue long N-terminal cysteine-rich domain (CRD), of unknown structure. Here, we use a combination of AlphaFold structural predictions and NMR spectroscopy to elucidate the structure of the SEP15 CRD, which mediates the interaction with UGGT. These data reveal that this domain forms a previously undescribed helical fold stabilized by three disulfide bonds between residues C10-C42, C21-C43, and C24-C39. Furthermore, our results validate our reported model of the UGGT/SEP15 complex and lay the foundation for future studies of its interaction with glycoprotein substrates.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: